Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06119061 · ClinicalTrials.gov registry record · Phase 4
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
A Phase 4 study of Subarachnoid Hemorrhage, Aneurysmal, sponsored by Aaron Cook.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06119061 is a Phase 4 study of Subarachnoid Hemorrhage, Aneurysmal that is actively recruiting participants, run by Aaron Cook. The registered enrollment target is 20 participants, below the 161-participant average among 8 other Subarachnoid Hemorrhage, Aneurysmal trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06119061, a Phase 4 study of Subarachnoid Hemorrhage, Aneurysmal, is actively recruiting participants, sponsored by Aaron Cook.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs were chosen as the target population because they frequently require prolonged admission to the intensive care unit and drainage of CSF in order to prevent hydrocephalus. The estimated sample size is 20 subjects. This is a prospective cohort of patients with SAH. Patients will be included if they have an in-dwelling EVD, aged 18-85 years old. Subjects will receive telavancin 10mg/kg (maximum 1000mg) every 24 hours for 3 consecutive doses. Serial serum and CSF samples will be obtained. An 8-hour urine collection will be completed on study day 2 in order to define the patient's measured creatinine clearance.
Conditions Studied
Interventions
- DRUG Telavancin Injection
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06119061
The ClinicalTrials.gov registry entry for NCT06119061 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 161-participant average among 8 other Subarachnoid Hemorrhage, Aneurysmal trials with a reported enrollment target (88% lower). The listed sponsor is Aaron Cook, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Subarachnoid Hemorrhage, Aneurysmal appearing as the primary indexed condition, and to 1 intervention - of which Telavancin Injection is the first listed.
NCT06119061 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT06119061 about?
NCT06119061 is a clinical study titled "Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage". The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs were chosen as the target population because they frequently require prolonged admission to the inten...
What is the current status of trial NCT06119061?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-07-02. Estimated completion is 2026-12.
What conditions does trial NCT06119061 study?
This clinical trial studies the following conditions: Subarachnoid Hemorrhage, Aneurysmal.
What interventions are being tested in trial NCT06119061?
The interventions under investigation include: Telavancin Injection (DRUG).
Who is sponsoring clinical trial NCT06119061?
This trial is sponsored by Aaron Cook, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06119061 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subarachnoid Hemorrhage, Aneurysmal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nimodipine Variability in SAH
RECRUITING
-
Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage
RECRUITING · NA
-
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
RECRUITING · Phase 2
-
Effects of Head-of-Bed on Intracranial Pressure
RECRUITING · NA
-
Augmented Renal Clearance in Neurocritical Care
RECRUITING
-
BLOCK-SAH - PPF-Block for Post-SAH Headache
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.